Panitumumab

• A Study of S241656 in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies Pending
  2025-523474-16-00 Phase I (FiH) 4 countries Institut De Recherches Internationales Servier IRIS
• ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting
  2024-514030-20-00 Phase II 4 countries Fondation Franc.Cancerologie Digestive
• A Study to Assess the Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Telisotuzumab Adizutecan in Part… Recruiting
  2024-512981-33-00 Phase II 6 countries AbbVie Deutschland GmbH & Co. KG
• Systemic antitumor treatment with or without pressurized intraperitoneal aerosol chemotherapy (PIPAC) for colon peritoneal metastases – a mu… Recruiting
  2024-514560-10-00 Phase II 1 country Institut De Cancerologie De L Ouest
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting
  2022-502352-31-00 Phase III 18 countries Amgen Inc.
• Randomized phase 2 study of Valproic acid combinEd with rechallenge anti-EGFR based regimen regimens in pretreated patients with RAS/BRAF wi… Recruiting
  2024-514420-16-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
• Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe… Recruiting
  2023-508724-35-00 Phase II 1 country Unicancer
• Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study Recruiting
  2024-518878-14-01 Phase IV 1 country Isala Klinieken Stichting
• A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi… Recruiting
  2023-509851-15-00 Phase III 3 countries Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets
• Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting
  2023-509551-14-00 Phase III 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
• Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and re… Recruiting
  2022-501308-90-00 Phase II 1 country Fondazione GONO G.I.
• Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trif… Recruiting
  2024-513723-16-00 Phase II 1 country Charite Universitaetsmedizin Berlin KöR
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Randomized and multicentre Phase II study of FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) alone or in combination with hepatic chemoe… Ended
  2024-517782-16-00 Phase II 1 country Grupo Espanol Multidisciplinar En Cancer Digestivo
• Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can… Ended
  2024-513296-41-00 Phase II 1 country Fondazione GONO G.I.
• Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi… Ended
  2024-510967-41-00 Phase III 2 countries Asociacion Grupo Tratamiento De Tumores Digestivos
• Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX) Ended
  2024-510645-34-00 Phase II 1 country Unicancer
• Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after fi… Ended
  2023-505356-22-00 Phase II 1 country Gruppo Oncologico Del Nord Ovest
• ​​Sotorasib and Panitumumab Versus Investigator’s Choice for Subjects with KRAS p.G12C Mutation (CodeBreaK 300)​ Ended
  2024-511187-81-00 Phase III 5 countries Amgen Inc.
• FFCD 1605- OPTIPRIME: A phase II study evaluating FOLFOX + panitumumab according to a ‘stop-and-go’ strategy with a reintroduction loop afte… Ended
  2024-518740-20-00 Phase II 2 countries Fondation Franc.Cancerologie Digestive
• MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY … Ended
  2024-517362-41-00 Phase II 1 country Fondation Franc.Cancerologie Digestive

Showing 1–21 of 21 trials